Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZN-c3 in Recurrent or Persistent Uterine Serous Carcinoma
2023-507324-23-00Phase 2Completed
- Sponsor
- K-Group Beta, Inc.
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of azenosertib in Serous endometrial adenocarcinoma (2 arms), sponsored by K-Group Beta, Inc. Primary endpoints: Part 1b: Frequency and severity of treatment-emergent adverse events (TEAEs), Part 1b: Incidence of ZN-c3 dose modifications due to TEAEs and 1 more. Started May 2024; status: completed.
02
Drugs
azenosertib
03
Conditions
Serous endometrial adenocarcinoma
Beyond the preview
Go deeper on 2023-507324-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507324-23-00.